SCHEMBL1459541

SCHEMBL1459541

Fc1cccc(F)c1-c1cc2cc(-c3ccc(C(F)(F)F)cc3C(F)(F)F)ccc2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 5/20 0.44
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.41
S1PR1 P21453 1/20 0.41
HPN P05981 1/20 0.39
TRPM8 Q7Z2W7 1/20 0.38
EDNRB P24530 1/20 0.38
EDNRA P25101 1/20 0.38
HSD17B1 P14061 1/20 0.38
HSD17B2 P37059 1/20 0.38
F7 P08709 1/20 0.36
F3 P13726 1/20 0.36
FFAR1 O14842 1/20 0.35
PTGES O14684 2/20 0.35
CYP1A1 P04798 1/20 0.34
CYP2C9 P11712 1/20 0.34
SCN9A Q15858 1/20 0.34
PTGS1 P23219 1/20 0.34
CDC7 O00311 1/20 0.33
DGAT1 O75907 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1460941 0.92 PTGES (0.42) TRPA1ALOX5APFEN1S1PR1HPN
SCHEMBL1460846 0.88 HPN (0.39) TRPA1HPNF7F3FFAR1
SCHEMBL1458883 0.87 PTGES (0.40) TRPA1HPNF7F3FFAR1
SCHEMBL1459665 0.84 KDM4E (0.46) TRPA1S1PR1
SCHEMBL1458951 0.83 PTGES (0.43) TRPA1HPNFFAR1PTGESCYP2C9
SCHEMBL12825438 0.82 TRPA1 (0.39) TRPA1S1PR1TRPM8HSD17B1HSD17B2
SCHEMBL1460085 0.82 KIF11 (0.42) TRPA1S1PR1KIF11
SCHEMBL1460084 0.80 NR3C1 (0.42) TRPA1S1PR1KIF11
SCHEMBL12826211 0.80 TRPA1 (0.38) TRPA1S1PR1TRPM8HSD17B1HSD17B2
SCHEMBL1464225 0.75 ALDH1A1 (0.46) FFAR1PTGESCYP1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2480529-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP claimed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO claimed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US claimed
EP-2480529-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. Hoffmann-La Roche AG (CH) 2012-08-01 EP disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO disclosed
WO-2011036130-A1 INDOLE DERIVATIVES AS CRAC MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 WO disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ALAM MUZAFFAR 2011-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110071150-A1 INDOLE DERIVATIVES AS CRAC MODULATORS ORAI1, RYR2, CACNA1E TRPA1 43/4885ALOX5AP 940/4885FEN1 4714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.